Onconova Therapeutics, Inc. (NASDAQ:ONTX) has a beta value of 2.02 and has seen 5,697,133 shares traded in the last trading session. The company, currently valued at $51.93 Million, closed the last trade at $0.28 per share which meant it lost -$0.01 on the day or -2.48% during that session. The ONTX stock price is -457.14% off its 52-week high price of $1.56 and 64.29% above the 52-week low of $0.1. If we look at the company’s 10-day average daily trading volume, we find that it stood at 14.71 Million shares traded. The 3-month trading volume is 22.01 Million shares.
The consensus among analysts is that Onconova Therapeutics, Inc. (ONTX) is a Hold stock at the moment, with a recommendation rating of 3. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 4 out of 4 have rated it as a Hold, with no one of them advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.03.
Onconova Therapeutics, Inc. (NASDAQ:ONTX) trade information
Despite being -2.48% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Oct 13 when the ONTX stock price touched $0.342 or saw a rise of 17.28%. Year-to-date, Onconova Therapeutics, Inc. shares have moved -26.14%, while the 5-day performance has seen it change 4.7%. Over the past 30 days, the shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX) have changed -12.09%. Short interest in the company has seen 13.22 Million shares shorted with days to cover at 0.6.
Wall Street analysts have a consensus price target for the stock at $1.83, which means that the shares’ value could jump 553.57% from current levels. The projected low price target is $0.3 while the price target rests at a high of $3. In that case, then, we find that the current price level is +971.43% off the targeted high while a plunge would see the stock lose 7.14% from current levels.
Onconova Therapeutics, Inc. (ONTX) estimates and forecasts
Figures show that Onconova Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -8.68% over the past 6 months, with this year growth rate of -91.95%, compared to 15.5% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 96% and 92.5% for the next quarter. Revenue growth from the last financial year stood is estimated to be +7.2%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +67.9% over the past 5 years. Earnings growth for 2020 is a modest +70%.